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Abstract
The number of older adults requiring dialysis is increasing worldwide, whereas the use of peritoneal dialysis (PD) in this population is
lower with respect to younger patients, despite the theoretical advantages of PD respect to hemodialysis. This is most likely due to the
concern that older patients may not be able to correctly and safely manage PD.
We aimed to prospectively compare clinical, nutritional and metabolic outcomes and measures of quality of life between younger
(<65 years old) and older (≥65 years old) patients on PD.
PD patients were enrolled and divided into 2 groups according to age (Group A<65 years, Group B ≥ 65 years). Clinical and
instrumental parameters, and quality of life were evaluated at baseline (start of PD) (T0) and at 24 months (T1). Technique survival,
mortality, total number of hospitalizations, and the index of peritonitis (episodes of peritonitis/month) were also evaluated.
Fifty-one patients starting PDwere enrolled. Group A included 22 patients (48.7±8.3 years), and Group B consisted of 29 patients
(74.1±6.4 years). At baseline, the 2 groups showed no differences in cognitive status, whereas Group A showed higher total
cholesterol (P= .03), LDL (P= .03), and triglycerides (P= .03) levels and lower body mass index (P= .02) and carotid intima media
thickness (P< .0001) with respect to Group B. At T1 Group B showed, compared to baseline, a significant reduction in albumin
(P< .0001) and phosphorus (P= .045) levels, while no significant differences on body composition, technique survival, total number
of hospitalizations, index of peritonitis, and quality of life indices were observed.
Our data do not show clinically relevant barriers to use PD in older adult patients, supporting its use in this population. Nutritional
and metabolic parameters should be carefully monitored in older PD patients.
Abbreviations: BMI = body mass index, BOLDE = Broadening Options for Long-Term Dialysis in the Elderly, CKD = chronic
kidney disease, CRP = C-reactive protein, DBP = diastolic blood pressure, ESV = erythrocyte sedimentation velocity, FGF =
fibroblast growth factor, HD = hemodialysis, HDL = high-density lipoprotein, IMT = intima-media thickness, iPTH = parathormone,
KDQOL-SF = Kidney Disease Quality of Life Short Form, LDL = low-density lipoprotein, LVM = left ventricular mass, MF-BIA =
multifrequency bioelectrical impedance analysis, nPCR = normalized protein catabolic rate, PD = peritoneal dialysis, RRF = residual
renal function, RRT = renal replacement therapy, SBP = systolic blood pressure.
Keywords: older adults, peritoneal dialysis, peritonitis, quality of life, renal replacement therapy
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1. Introduction
The prevalence of chronic kidney disease (CKD) is increasing in
older adults worldwide [1,2] and the most prevalent causes of loss
of kidney function are diabetes, hypertension, and vascular
disease.[3] As cardiovascular disease is better managed in the
general population, patients live longer and the risk to develop
CKD in the older adults is significantly higher.[3] Therefore, the
number of older adults needing renal replacement therapy (RRT)
is steadily increasing.[4] Studies have shown that dialysis can
significantly impact on life expectancy and quality of life, but only
in a limited number of patients the peritoneal dialysis (PD) is
considered as the first therapeutic option.[5,6] This is probably
due to the concern that older adult patients may not be able to
safely manage this home-based treatment or due to a perception
that PD is associated with greater risk of complications.[7] From
the other side, hemodialysis (HD) can be negatively perceived by
patients because of the long time to be spent in the HD
facilities.[8,9] A large number of older patients do not positively
accept to start a HD treatment, while the proportion of older
adults on PD is considerably lower with respect to younger
patients. Despite different studies have shown that survival and
quality of life of older adults on PD do not differ from HD, the
option to implement PD is still largely lacking.[7–10] Furthermore,
the North Thames Dialysis Study, a prospective study conducted
on patients ≥ 70 years old, has shown that survival, hospitaliza-
tion, and quality of life were similar between patients on HD and
those on PD.[5,11,12] Older patients are often socially isolated and
often depressed due to loss of independence. Moreover, the
associated vascular disease results in a high risk of failure for
vascular access for the HD treatment. This results in increased
reliance on venous access, with higher risk of infection.[5,8,11–13]
Failure of vascular access can necessitate frequent hospital
admissions for radiological and surgical procedures. Also,
cardiac disease can cause hypotension and arrhythmias during
HD session and older adults often feel “weakened” after a HD
treatment. In addition, many patients cannot reach the dialysis
center independently and require transportation provided by the
hospital.[8,12,14] The problem is to determine whether older adults
can safely manage PD. Several older adults can be trained to do
their own PD, although this may take longer time. Family
members are often willing to help with all or part of the
procedure, and in some parts of Europe, the use of community
nurses enables older adults to be on PD in their own homes.[15–17]
Furthermore, we should consider that PD is a less expensive
treatment than HD.[18]
The aim of this study was to compare clinical, instrumental
parameters, quality of life, and hospitalizations between younger
(< 65 years old) and older (≥65 years old) patients on PD.
2. Patients and methods
The study protocol was approved by the Local Clinical Research
Ethics Committee. The study conforms to the principles outlined
in the Declaration of Helsinki and we obtained a written consent
by all patients before the enrollment.
2.1. Study design
We performed a prospective study on clinically stable patients
starting PD at the Peritoneal Dialysis Unit, Policlinico Umberto I,
Sapienza University of Rome, Rome, Italy.
We enrolled consecutive patients from January 2009 to August
2014, eligible to perform PD.[6] Patients were divided into 2
groups in accordance to age: the first group (Group A) included
patients aged<65 years and the second group patients aged
≥ 65 years (Group B). Clinical, laboratory, instrumental
parameters and quality of life were evaluated at baseline (start
of PD) (T0) and at 24 months (T1). Kt/V urea and creatinine
clearance (L/week/1.73 m2) were calculated. These values were
measured by collecting the dialytic effluent over a 24-hour period
and by a plasma sample. Residual renal function (RRF)
(glomerular filtration rate; mL/minute) was calculated as mean
of renal clearances of urea and creatinine, collecting all urine
output over the same 24-hour period and dialysate creatinine
clearance was obtained from 24-hour collections of dialysate. We
also used normalized protein catabolic rate (nPCR) (grams
per kilogram per day) calculated from dialysis kinetic model-
ing.[19–21] We evaluated the technique survival, the mortality, the
“index of peritonitis,” expressed as months free from peritonitis
(episodes of peritonitis/months), and the number of hospital-
izations at T0 and T1 in both groups. Peritoneal dialysis-
associated peritonitis was defined as a symptom or sign
(abdominal pain, fever, and turbid dialysate) combined with
an effluent cell count of more than 100/mL leukocytes, with at
least 50% polymorphonuclear neutrophilic cells.[13] The Kidney
Disease Quality of Life Short Form (KDQOL-SF) was also
administered in both groups.
2.2. Inclusion criteria
Patients aged >18 years starting PD.
2.3. Exclusion criteria
Patients with cancer, liver disease, human immunodeficiency
virus, and those who had been on HD (before starting PD) for
more than 30 days and patients with previous renal transplanta-
tion were excluded. Patients who refused to give consent and
patients with missing clinical data were also excluded.
2.4. Anthropometric assessments
Patients were evaluated before the first replacement with empty
peritoneum in the morning. During routine visits, height and
weight were measured with the patient wearing indoor clothing
before intraperitoneal dialysate. Body weight was determined to
the nearest 0.1kg using a calibrated digital scale. Body mass index
(BMI) was calculated using the formula [weight (kg)/height (m2)].
2.5. Laboratory measurements
Blood were collected in the morning after an overnight fasting (at
least 12hours). In all patients, the levels of fasting plasma glucose
(mg/dL), total serum cholesterol (mg/dL), triglycerides (mg/dL),
high-density lipoprotein (HDL) (mg/dL), low-density lipoprotein
(LDL) (mg/dL), serum nitrogen (mmol/L), serum calcium (mg/
dL), phosphate (mg/dL), sodium (mEq/L), potassium (mEq/L),
serum uric acid (mg/dL), C-reactive protein (CRP) (mg/dL),
and erythrocyte sedimentation velocity (ESV) (mm/H), were
measured using standard automated techniques. Serum albumin
(g/dL) was determined by bromcresol purple method. Parathor-
mone (iPTH) (pg/mL) was measured using a 2-site assay that
measures “intact” hormone. LDL-cholesterol was calculated
using the Friedewald equation: LDL (mg/dL)= total cholesterol
HDL (triglicerydes/5).Arterial bloodgas analysiswas performed
using a blood gas analyzer (Nova Biomedical Corporation
Waltham MA, USA).
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2.6. Blood pressure measurements
Systolic and diastolic blood pressure (BP) levels were measured in
patients on PD during routine visits. Clinic BP measurements
were made 3 times after 10 minutes of rest in a seated position
using a standard automated sphygmomanometer and cuffs
adapted to the arm circumference, according to the British
Hypertension Society guidelines. The mean values for systolic BP
(SBP) and diastolic BP (DBP) were calculated for all partic-
ipants.[22] The systolic and diastolic BP levels were taken as the
points of appearance and disappearance of Korotkoff sounds,
respectively. Hypertension was defined as SBP >140 mmHg or
DBP >90 mmHg on repeated measurements.
2.7. Bioelectrical impedance analysis
Multifrequency bioelectrical impedance analysis (MF-BIA)
(Akern, Florence, Italy) was performed using an impedance
plethysmograph that emits an 800-mA, 50-kHz alternating
current.Measurements were takenwith patients being in a supine
position for 5 minutes, according to the manufacturer’s guide-
lines. The analysis of the entire body involves the placement of 2
electrohydraulic injectors at the back of the hands and feet at the
distal ends of metacarpals and metatarsals, and 2 measuring
electrodes were placed on the dorsal surfaces of the wrists and
ankles. We proceeded to the recording of impedance, resistance,
reactance, and phase angles and the subsequent transformation
into estimates of lean body mass, body fat, cell mass, total body
water, and intracellular water.[23,24]
2.8. Common carotid intima-media thickness (IMT)
At T0 and T1, right and left carotid ultrasound was blindly
performed by an experienced sonographer who was unaware of
the characteristics of the patients under examination. Participants
were studied with the high-resolution B-mode ultrasound
machine Toshiba Aplio XV (Toshiba AplioxV, Toshiba Ameri-
can Medical Systems, Inc., Tustin, CA) equipped with a 5- to 12-
MHz linear transducer with a 0.01-mm resolution, following a
standardized vascular protocol. Three different longitudinal
views (anterior oblique, lateral, and posterior oblique) and a
transverse viewwere obtained. IMTwasmeasured at three points
on the far walls of both left and right distal common carotid
arteries, carotid bulb, and the proximal portion of the internal
carotid arteries. Images were captured in end diastole triggered by
electrocardiographic recording. The mean IMTwas computed as
the average IMT on both sides. The value of IMT was considered
normal when between 0.55 and 1mm.[25,26]
2.9. Echocardiography
Transthoracic echocardiography after emptying the peritoneal
cavity was performed. M-mode 2D echocardiographic exami-
nations by a single experienced sonographer in the echocardio-
graphy laboratory and using a standard institutional protocol
were completed.[27,28] Commercially available instruments
(Toshiba AplioxV, Toshiba American Medical Systems, Inc.,
Tustin, CA) equipped with 2.25- to 7.5-MHz imaging trans-
ducers were used; the patients were in the left decubitus position,
and the sonographer was blinded to all clinical details of the
patients. All echocardiographic data according to the guidelines
of the American Society of Echocardiography were recorded.[29]
The end-diastolic and end-systolic left ventricular internal
diameter, interventricular septum thickness, and posterior wall
thickness were measured. The left ventricular mass (LVM) was
estimated following Devereux’s formula normalized by body
surface area and height.[30]
2.10. Kidney Disease Quality of Life Short Form
The KDQOL-SF is a self-report measure developed for
individuals with kidney disease and those on dialysis. It is a
shorter version of a measure developed by the same authors. It
includes 43 kidney disease-targeted items, such as the effects of
the disease of activities of daily living, work status, and social
interaction, and 36 items that provide a measure of physical and
mental health. The 80 items take about 16 minutes to complete.
The item role physical, emotional well-being, and weight of
kidney disease is assigned a score from 0 to 4; emotional role
instead corresponds to the item a score from 0 to 3. The total
score of the questionnaire ranges from 0 to 15, associating at the
greater value the lower perceived well-being.[31]
2.11. Statistical analysis
All continuous variables were expressed as mean± standard
deviation, and categorical variables were expressed as numbers
(percentage). Student t-tests and ANOVA were performed to
determine differences between groups, as appropriate. Binomial
test or x2 test was used for the comparison of categorical data. A
probability value of P< .05 was considered to be statistically
significant. Data management and analysis were performed using
IBM SPSS Statistics 17 forWindows software (IBMCorporation,
New Orchard Road Armonk, New York, NY).
3. Results
Atotal of 51patients (28males)were enrolled.GroupA included 22
patients (mean age: 48.7±8.3 years), 21%were on automated PD.
Group B consisted of 29 patients (mean age of 74.1±6.4 years),
72% are on continuous ambulatory PD. The etiology of end-stage
renal disease (ESRD) was autosomal dominant polycystic kidney
disease in4patients (18%) inGroupAand2patients (7%) inGroup
B; chronic glomerulonephritis in 4 patients (18%) inGroupA and 6
patients (21%) inGroup B; diabetic nephropathy in 2 patients (9%)
inGroupAand6patients (21%) inGroupB; chronic pyelonephritis
in 2 patients (9%) in Group A and 1 patient (3%) in Group B;
hypertensive nephrosclerosis in 6 patients (27%) inGroupA and 12
patients (41%) in Group B; and unknown in 4 patients (18%) in
Group A and 2 patients (7%) in Group B.
3.1. Baseline characteristics
Patient’s characteristics at baseline (T0) are shown in Table 1. In
summary, there were no significant differences between the 2
groups, except for higher values in Group A with respect to
Group B of total cholesterol (mg/dL) (195.4±43.3 vs 172.2±
32.3; P= .03), LDL (mg/dL) (125.2±34.3 vs 103.9±31.1;
P= .03), and triglycerides (mg/dL) (137.8±51 vs 110.1±35.5;
P= .03), while Group A, with respect to Group B, had a
significant lower BMI (kg/m2) (23.45±3.08 vs 26.05±3.50;
P= .02), and carotid IMT (mm) (0.97±0.32 vs 1.54±0.31;
P< .0001). The prevalence of comorbidities, including diabetes
and cardiovascular diseases, was not statistically different
between the 2 groups, as shown in Table 2.
At T0 the 2 groups appeared relatively homogeneous on the
items General Health, Role Physical, Role Emotional, and Social
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Function of the KDQOL-SF test. Also, the items cognitive
function (87.18±11.42 vs 89.67±14.72; P= .51) and Physical
Function (63.24±24.30 vs 53.75±21.49; P= .15) did not show
statistically significant differences between the 2 groups at T0.
3.2. Follow-up results
At T1 in Group B, a significant reduction in albumin (P< .0001)
and phosphorus levels was observed (P= .045) (Table 3). KT/V,
RRF and nPCRwere not different between the 2 groups (3.0±1.2
vs 2.5±0.80, P= .08; 7.53±4.21 vs 10.21±5.59, P= .28; 1.05±
0.17 vs 0.95±0.19, P=0.29, respectively). No significant
changes in body composition parameters were shown (Table 3)
and no differences in the index of peritonitis (episodes of
peritonitis/month) were registered (Group A: 0.03±0.001 vs
Group B: 0.03±0.002; P= .99) In addition, the survival of the
technique during the follow-upwas of 77.2% (n=17) and 72.4%
(n=21) (P= .54) and the patient’ s survival rate at the end of the
follow-up was 95.4% (n=21) in Group A and 86.2% (n=25) in
Group B (P= .05). We reported 9 hospitalizations in Group A
and 11 in Group B (P= .94). The reasons for hospitalization were
comparable between the 2 groups (including cardiovascular and
cerebrovascular events). Both groups did not differ regarding the
item cognitive functions of the KDQOL-SF (Group A 86.27±
11.42 vs Group B 91.25±9.34; P= .09). And they appeared
relatively homogeneous on the items General Health, Role
Physical, Role Emotional, Social and Physical Function and
Satisfaction care. Also, Group A had a higher score for Energy
/Fatigue (Group A 59.4±13.1 vs Group B 54.1±23.9; P= .35)
and Sleep Quality (Group A 67.7±13.3 vs Group B 60±23.2;
P= .17), although not statistically significant.
4. Discussion
Chronic kidney disease is a common condition among older
adults and only a few patients with ESRD are treated with PD.[32–
34] The BroadeningOptions for Long-TermDialysis in the Elderly
(BOLDE) study has shown that older patients can successfully
manage PD, and that in 2 closely matched demographic groups of
older dialysis patients on PD and HD, quality of life was similar,
but with significantly less perception of intrusion of the disease in
their lives in the PD group.[12,35,36] In our study, there were also
no statistically significant differences in the index of peritonitis
and in term of mean survival of the technique between younger
and older patients. In HD, complications of the vascular access,
intradialytic hypotension, and impaired autonomic function with
hemodynamic instability, bleeding, and amyloidotic arthropathy
represent the most relevant limitations, especially in older
adults.[7,8,37] Authors suggested that patients on PD perceived
lower distress and higher psychological well-being compared
with patients undergoing other replacement therapies.[38,39]
Moreover, several studies indicated that the psychological impact
Table 1
Patient’s characteristics at baseline (T0).
Patient’s characteristics Group A (n=22) Group B (n=29)
Body mass index, kg/m2 23.45±3.8 26.05±3.5
∗
APD, % 36% 27%
CAPD, % 64% 73%
Hb, g/dL 11.12±1.7 10.9±1.6
Albumin, g/L 4.05±0.6 4.08±0.3
Serum creatinine, mg/dL 6.4±1.6 6.1±2.3
BUN, mg/dL 153.5±42.1 137.6±44.2
Natrium, mEq/L 138.4±11.3 140.8±4.3
Potassium, mEq/L 4.7±0.7 4.6±0.5
Calcium, mg/dL 9.4±0.8 9.3±0.8
Phosphorus, mg/dL 4.8±0.8 5.02±1.3
Ipth, pg/mL 231.6±154.6 212.8±111.4
Total cholesterol, mg/dL 195.4±43.3 172.2±32.3†
HDL, mg/dL 51.2±16.8 48.4±16.4
LDL, mg/dL 125.2±34.3 103.9±31.1†
Triglycerides, mg/dL 137.8±51 110.1±35.5†
Serum iron, mg/dL 66.2±28.2 53.5±16.0
Serum ferritin, ng/mL 147.5±116 131.1±107.7
Serum transferrin, mg/dL 217.7±43 207.8±51.1
Fibrinogen, mg/dL 460.2±108.1 500.2±116.1
CRP, mg/dL 1.13 ±0.85 0.84±0.23
CIMT, mm 0.97±0.32 1.54±0.31‡
LVMI, g/m2 111.2±23.1 123.8±29.4
KT/V 2.81±0.97 2.85±1.52
RRF 9.6±9.85 10.11±9.95
Data are show as mean± standard deviation or %.
∗
P= .02.
† P= .03.
‡ P< .0001.
APD= automated peritoneal dialysis, BUN=blood urea nitrogen, CAPD= continuous ambulatory
peritoneal dialysis, CIMT= carotid intima-media thickness, CRP=C-reactive protein, eGFR= estimated
glomerular filtration rate, Hb=hemoglobin, HDL=high-density lipoprotein, iPTH= intact parathormone,
LDL= low-density lipoprotein, LVMI= left ventricular mass index, RRF= residual renal function.
Table 2
Comorbid conditions in Group A and Group B.
Group A
(n=22)
Group B
(n=29) P
Comorbid condition, n (%) 20 (91) 29 (100) .35
Arterial hypertension, N (%) 15 (68.1) 24 (82.7) .38
Diabetes, N (%) 2 (9) 6 (21) .46
Ischemic, hypertensive or
valvular heart disease, N (%)
3 (13.6) 9 (31) .26
Peripheral vascular disease, N (%) 2 (9) 7 (24.1) .30
Transient ischemic attack or stroke, N (%) 1 (4.5) 5 (17.2) .34
Table 3
Biochemical, inflammatory and body composition variables in Group A and Group B at T0 and T1.
Variables Group A (T0) Group A (T1) P Group B T0 Group B T1 P
Albumin, g/dL 4.05±0.61 4.0±0.54 .77 4.08±0.39 3.70±0.44 <.0001
Phosphorus, mg/dL 4.85±0.85 5.38±1.19 .10 5.02±1.30 4.32±1.30 .045
nPCR, g/kg/day 1.1±0.14 1.05±0.17 .29 0.98±0.20 0.95±0.19 .56
CRP, mg/dL 1.13±0.85 1.21±0.32 .68 0.84±0.23 1.07±0.85 .17
FFM, % 76.1±6.9 78.5±8.6 .31 73.4±8.7 70.5±11.6 .28
FM, % 23.9±6.9 21.5±8.6 .31 28.07±9.02 29.5±11.6 .60
ECF/TBW 0.40±0.05 0.42±0.06 .23 0.41±0.05 0.41±0.03 .57
CRP=C-reactive protein, ECF = extra-cellular fluid, FFM = fat free mass, FM = = fat mass, nPCR = normalized protein catabolic rate, TBW = total body water.
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of a disease can affect compliance with medical treatments.[40,41]
A study showed that the non-adherence to medical prescriptions
is a consistent concern in patients on PD causingmajor difficulties
to manage their treatments,[41] that may include the adherence
to the dietetic regimen. This aspect should be taken into
consideration to effectively improve patient’s outcomes. In fact,
previous studies showed that patients on renal replacement
therapy presented lower adherence to therapy, contributing to a
greater morbidity and earlier mortality.[42] Our study showed
significant modifications in serum phosphorus levels during the
follow-up, suggesting a possible lower adherence to the therapy
and to the dietetic regimen in younger patients and better
acceptance of the specific food restriction in older adults. Patients
with ESRD present a markedly increased cardiovascular risk and
increased serum phosphate levels can have several negative effects
on organ functions being associated with increased cardiovascu-
lar events and mortality.[43,44] The relationship between serum
phosphorus and cardiovascular mortality has been also evaluated
in patients in the REIN and NANHES III study,[45,46] suggesting
that phosphorus is an independent predictor of cardiovascular
mortality. Moreover, the phosphate-regulating hormone fibro-
blast growth factor (FGF)-23 is directly associated with left
ventricular hypertrophy. Yamamoto et al[47] have shown that
higher serum phosphorus intake is associated with higher left
ventricular mass. Short-term studies have also shown that dietary
phosphate reduction effectively decreases FGF-23 levels.[48]
Moreover, our study showed a significant reduction of albumin
levels in older patients, suggesting an increased risk of protein-
energy wasting in this population, although albumin is a poor
marker of nutrition, since it also represents an indirect measure of
inflammation. Indeed, PD patients lose albumin in the dialysate,
which could also cause hypoalbuminemia, and presumably older
patients are not able to replace the losses, due to reduced liver
function.[49] Other clinical and instrumental data, including body
composition, showed similar results in both groups during the
24-month follow-up, suggesting an equally effective maintenance
of most of the clinical and metabolic parameters during PD.
Although Group B showed higher BMI with respect to Group A,
we did not find differences in term of body composition, in
particular regarding lean body mass. In fact, we were expecting a
significant reduction of muscle compartment, which is a common
feature among older patients. Interestingly, we observed a stable
hydration status in patients of both groups. Also, echocardio-
graphic indexes, including LVM index, which represents a
clinical parameter to monitor cardiac hypertrophy [50] and
possibly skeletal muscle mass modifications,[51] remained
unchanged during the follow-up in the 2 groups. We did not
observe modifications in atherosclerosis indexes (carotid IMT),
although they are age-related and no significant differences in the
number of hospitalizations. The 2 groups were comparable
regarding specific items of the KDQOL-SF and group B showed
no physical or cognitive disabilities that may justify the lack of
use of PD.
We acknowledge the limitations of our study. In particular, we
enrolled a relatively small, selective cohort of PD patients and a
larger population appears necessary to confirm our results.
Furthermore, as shown in our results, a significant proportion of
patients were on several medications with potential impact on
different metabolic indices that may have possibly confounded
the results.
Our study showed similar results in term of clinical outcomes
between younger and older patients treated with PD. We did not
observe increased risk of peritonitis between groups and we
found a good control of different clinical parameters and
perception of general health during the 24-month follow-up. Our
data support the expansion of PD procedure in older adults.
Patients’ preferences, after a precise information regarding
dialysis techniques, should be elicited and carefully considered
by healthcare professionals, considering the lower costs of PD
compared toHD.[8,9] Larger randomized clinical trials are needed
to confirm the results here presented.
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